Next date
None yet
Trials
4 active
8 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA class
- Tested for
- COVID-19 (4 trials)
- Main trialPhase 3
- “The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.”In the company’s words, NCT04292730 on ClinicalTrials.gov
- Other names
- GS-5734 · Veklury
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 29 Apr 2020 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | |
| Phase 3Terminated | 20 Apr 2022 | Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) | |
| Phase 2/3Completed | 10 Feb 2023 | Study of Remdesivir in Participants Below 18 Years Old With COVID-19 | |
| Phase 1/2Completed | 26 Feb 2021 | Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation | |
| Phase 2Authorised | not given | OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study | |
| Phase 2Authorised | not given | SAFETY AND EFFICACY OF A 10-DAY COURSE OF REMDESIVIR TO PREVENT SEVERE COVID-19 IN ASYMPTOMATIC OR PAUCISYMPTOMATIC SARS-COV-2-POSITIVE KIDNEY TRANSPLANT RECIPIENTS: A SINGLE-ARM PROOF-OF-CONCEPT INTERVENTIONAL TRIAL | |
| Phase 2Authorised | not given | Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) – A phase 2 proof-of-concept, national, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy of remdesivir in adult patients hospitalized for TBE | |
| Phase 2Authorised | not given | Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026